New Executive VP at Recipharm

Contract Development and Manufacturing Organisation, Recipharm, has appointed Henrik Stenqvist as Recipharm’s new Executive Vice President and Chief Financial Officer.

He will be based at the company’s headquarters in Stockholm, Sweden. Henrik Stenqvist brings 24 years’ finance and management experience to Recipharm.

Prior to joining Recipharm he served as CFO of the Meda Group and held other leading finance positions in the pharmaceutical industry. He holds a degree in Finance and Business Administration from the University of Linkoping, Sweden.

Thomas Eldered, Chief Executive Officer of Recipharm, said: “Henrik's extensive experience and perspectives in finance, business and strategic development in the pharmaceutical industry make him a great fit for Recipharm as we continue on our strong growth path.”

You may also like

Training & Education

Women in pharma: the battle against mansplaining continues

Prejudice in the workplace is an affliction suffered by many, but how can the industry be free from this nasty virus?
Manufacturing

Recipharm, Medspray and Resyca enter into license agreement to develop nasally-delivered soft mist drug products

Recipharm, Medspray and Resyca have entered an exclusive collaboration and licensing agreement to develop soft mist nasal delivery devices for single and combination drug products.
Manufacturing

Overcoming bio/pharmaceutical production hurdles: an industry insider perspective

From F-gas regulation to finance and from biologics to personalised medicines, the global drug production environment faces a number of challenges that could potentially stifle innovation and profitability. Dr Kevin Robinson (KSR) recently spoke to key players in the supplier and outsourcing community to better understand what services and solutions are available to keep the pipeline flowing
Manufacturing

Recipharm’s analytical lab brings testing capabilities to global markets

Fully cGMP/cGLP compliant, the 5,000 sqft lab will expand Recipharm’s existing analytical capabilities and provide support for biotech and pharma customers
Manufacturing

BES completes $4.8m refurb for Recipharm

The 4000 sqm facility, located in King’s Lynn, has seen an extensive redesign and refurbishment
Manufacturing

Recipharm extends commercial manufacturing for RedHill’s drug

Talicia is eligible for eight years of US market exclusivity under QIDP designation and its patent protection extends at least until 2034
Manufacturing

Recipharm expands services for pMDI propellants

The company's device development team recently completed a three-year Innovate UK (IUK) knowledge transfer partnership research programme with UK universities
Subscribe now